— Results will likely “motivate a practice modification,” editorialists state
by Mike Bassett, Staff Writer, MedPage Today
May 10, 2023
Allogeneic hematopoietic stem cell transplant (HSCT) was related to considerable enhancements in progression-free survival (PFS) in clients with innovative cutaneous T-cell lymphomas (CTCLs), according to the tendency score-matched regulated CUTALLO research study from France.
In an intention-to-treat (ITT) population of 99 clients, mean progression-free survival was 9 months in the HSCT group compared to 3 months in the non-HSCT group (HR 0.38, 95% CI 0.21-0.69, P< 0.0001), reported Adèle de Masson, MD, of Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, and associates.
The 1-year cumulative occurrence of regression in the HSCT group was 45.4% versus 86.0% in the non-HSCT group (cause-specific HR 0.29, 95% CI 0.17-0.58), while the 1-year cumulative occurrence of non-relapse death was 8.5% compared to 0%, respectively (P=0.017), they kept in mind in The Lancet
The 1-year PFS rate in the matched HSCT group was 50.5% compared to 14.3% in the matched non-HSCT group (HR 0.33, 95% CI 0.17-0.61).
CTCLs, consisting of mycosis fungoides and Sézary syndrome, are uncommon malignancies of skin-homing T cells. Advanced-stage CTCLs are connected with a typical total survival of less than 5 years. They likewise considerably impact lifestyle, causing noticeable skin modifications such as erythroderma, along with growths, pruritus, infections, discomfort, and asthenia.
Couple of treatments have actually been revealed to enhance PFS in potential regulated research studies, and none have actually been revealed to increase general survival, kept in mind de Masson and coworkers.
Case series have actually recommended that allogeneic HSCT “possibly causes a graft-versus-lymphoma impact leading to lasting CTCLs remission in some individuals,” they included.
In the ITT population, 30 individuals passed away– 22% of the HSCT group and 41% of the non-HSCT group. There was a non-significant advantage in average general survival observed for the HSCT group (not reached vs 26.9 months, respectively).
In a commentary accompanying the research study, Madiha Iqbal, MBBS, MD, and Mohamed Kharfan-Dabaja, MD, both of the Mayo Clinic Cancer Center in J